Revised International Prognostic Scoring System (IPSS-R) for MDS

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Very low risk0–1.5
  • Low risk1.5–3
  • Intermediate risk3–4.5
  • High risk4.5–6
Direct Clinical Answer

The Revised International Prognostic Scoring System (IPSS-R) for MDS calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include cytogenetics. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Prognostic scoring for myelodysplastic syndromes: cytogenetics, blasts, hemoglobin, platelets, ANC.

Clinical Indication

The Revised International Prognostic Scoring System (IPSS-R) for MDS is indicated for bedside clinical practice to support Prognostic scoring for myelodysplastic syndromes: cytogenetics, blasts, hemoglobin, platelets, ANC.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

Points: cytogenetics 0-4, blasts 0-3, Hb 0/1/1.5, platelets 0/0.5/1, ANC 0/0.5

Input Parameters

NameTypeRequiredDescription
cytogeneticsstringYesCytogenetic risk
bm_blastsstringYesBone marrow blasts
hemoglobinstringYesHemoglobin
plateletsstringYesPlatelets
ancstringYesANC

Score Interpretation & Guidance

RangeStageDescription
0–1.5Very low riskVery low risk
1.5–3Low riskLow risk
3–4.5Intermediate riskIntermediate risk
4.5–6High riskHigh risk
6–20Very high riskVery high risk

Evidence-Based References (EBM)

  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.

Related calculators